Flynn James E 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-01 6:06 pm Sale | 2025-07-30 | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 7,610,217 7.750% | -1,023,320 (-11.85%) | Filing |
| 2025-07-22 7:38 pm Sale | 2025-07-18 | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 8,633,537 8.790% | -1,090,971 (-11.22%) | Filing |
| 2025-07-02 08:24 am Sale | 2025-07-02 | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 9,724,508 9.900% | -790,149 (-7.51%) | Filing |
| 2025-03-24 7:57 pm Sale | 2025-03-20 | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 10,514,657 10.720% | -563,270 (-5.08%) | Filing |
| 2022-11-18 5:06 pm Purchase | 2022-11-08 | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 11,077,927 11.810% | 11,077,927 (New Position) | Filing |